Chapter 6 Contraception in Women with Epilepsy. Pharmacokinetic Interactions, Contraceptive Options, and Management

International Review of Neurobiology

Volumn 83, Issue , 2008, Pages 113-134

  Dutton, Caryn ^a   Foldvary Schaefer, Nancy ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CONTRACEPTIVE AGENT;

DRUG CONTRAINDICATION; DRUG INTERACTION; EPILEPSY; FEMALE; HUMAN; METABOLISM; REVIEW;

ANTICONVULSANTS; CONTRACEPTIVE AGENTS; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS;

EID: 53049107058     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(08)00006-8     Document Type: Review

References (71)

1. American Academy of Neurology. (AAN). Practice parameter: Management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 51 (1998) 944-948
2. American College of Obstetricians and Gynecologists. (ACOG). Use of hormonal contraception in women with co-existing medical conditions. Obstet. Gynecol. 107 (2006) 1453-1472 ACOG Practice Bulletin no. 73
3. Asbell B. The Pill: A Biography of the Drug that Changed the World (1995), Random House, New York, NY
4. Audet M.C., Moreau M., Koltun W.D., Waldbaum A.S., Shangold G., Fisher A.C., and Creasy G.W. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive. JAMA 285 (2001) 2347-2354
5. Back D.J., Bates M., Bowden A., Breckenridge A.M., Hall M.J., Jones H., MacIver M., Orme M., Perucca E., Richens A., Rowe P.H., and Smith E. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 22 (1980) 495-503
6. Bartoli A., Gatti G., Cipolla G., Barzaghi N., Veliz G., Fattore C., Mumford J., and Perucca E. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 38 (1997) 702-707
7. Bounds W., and Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J. Fam. Plann. Reprod. Health Care 28 (2002) 78-80
8. Browning K., Birnbaum A., Montgomery J., Newman M.L., Clements S.D., and Pennell P.B. Lamotrigine clearance is increased by estrogen-containing contraceptives. Neurology 66 Suppl. 2 (2006) A273
9. Christensen J., Petrenaite V., Atterman J., Sidenius P., Ohman I., Tomson T., and Sabers A. Oral contraceptives induce lamotrigine metabolism: Evidence from a double-blind, placebo-controlled trial. Epilepsia 48 (2007) 484-489
10. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16 (2002) 263-272
11. Crawford P., and Lee P. Gender difference in management of epilepsy-What women are hearing. Seizure 8 (1999) 135-139
12. Crawford P., Chadwick D., Cleland P., Tjia J., Cowie A., Back D.J., and Orme M.L. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 33 (1986) 23-29
13. Crawford P., Chadwick D.J., Martin C., Tjia J., Back D.J., and Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br. J. Clin. Pharmacol. 30 (1990) 892-896
14. Darney P.D. Time to pardon the IUD?. New Engl. J. Med. 345 (2001) 608-610
15. Davis A.R., Pack A., Camus A., Yoon A., and Krizer J. Patient knowledge of teratogenicity and contraceptive interactions of antiepileptic drugs. Obstet. Gynecol. 109 (2007) 60S
16. Davis A.R., Pack A.M., Kritzer J., Yoon A., and Camus A. Reproductive history, sexual behavior, and use of contraception in women with epilepsy Personal communication to Caryn Dutton. Contraception 77 (2007) 405-409 In press
17. Diamond M.P., Greene J.W., Thompson J.M., VanHooydonk J.E., and Wentz A.C. Interaction of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 31 (1985) 623-632
18. Dickens M., and Chen C. Lamotrigine: Chemistry, biotransformation and pharmacokinetics. In: Levy R.H., et al. (Ed). Antiepileptic Drugs (2002), Raven Press, New York, NY 370-379
19. Doose D.R., Wang S.S., Padmanabhan M., Schwabe S., Jacobs D., and Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44 (2003) 540-549
20. Eldon M.A., Underwood B.A., Randinitis E.J., and Sedman A.J. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 50 (1998) 1146-1148
21. Espir M., Walker M., and Lawson J. Epilepsy and oral contraception. Br. Med. J. 1 (1969) 294-295
22. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. (FFPRHC). Faculty statement from the CEU: Levonelle 1500 and the use of liver enzyme inducing drugs (2006). http://www.ffprhc.org.uk/admin/uploads/563_Levonelle1500KeyStatement.pdf Available at
23. Fattore C., Cipolla G., Gatti G., Limido G.L., Sturm Y., Bernasconi C., and Perucca E. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40 (1999) 783-787
24. Finer L., and Henshaw S.K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Fam. Plann. Perspect. 38 (2006) 90-96
25. Foldvary-Schaefer N., and Falcone T. Catamenial epilepsy: Pathophysiology, diagnosis, and management. Neurology 61 (2003) S2-S15
26. Foy R., Penney G., and Greer I. The impact of national clinical guidelines on obstetricians in Scotland. Health Bull. 59 (2001) 364-372
27. Galimberti C., Mazzucchelli I., Arbasino C., et al. Increased apparent oral clearance of vaproic acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia 47 (2006) 1569-1572
28. Griffith S.G., and Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin. Ther. 26 (2004) 2056-2065
29. Grimes D.A. Intrauterine devices (IUDs). In: Hatcher R.A., et al. (Ed). Contraceptive Technology (2004), Ardent Media, Inc., New York, NY 495-502
30. Harrison-Woolrych M., and Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): A case series from postmarketing experience in Australia. Contraception 71 (2005) 306-308
31. Hatcher R.A. Depo-Provera injections, implants, and progestin-only pills (Minipills). In: Hatcher R.A., et al. (Ed). Contraceptive Technology (2004), Ardent Media, Inc., New York, NY 461-494
32. Herzog A., Klein P., and Ransil B. Three patterns of catamenial epilepsy. Epilepsia 38 (1997) 1082-1088
33. Jensen J. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: An overview. Obstet. Gynecol. Surv. 60 (2005) 604-612
34. Kennedy K.I., and Trussell J. Postpartum contraception and lactation. In: Hatcher R.A., et al. (Ed). Contraceptive Technology. 17th ed. (2004), Ardent Media, Inc, New York 575-600
35. Kenyon I.E. Unplanned pregnancy in an epileptic. Br. Med. J. 1 (1972) 686-687
36. Klosterskov Jensen P., Saano V., Haring P., Svenstrup B., and Menge G.P. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 33 (1992) 1149-1152
37. Krauss G.L., Brandt J., Campbell M., Plate C., and Summerfield M. Antiepileptic medication and oral contraceptive interactions: A national survey of neurologists and obstetricians. Neurology 46 (1996) 1534-1539
38. Mattson R., Cramer J.A., Caldwell B., and Siconolfi B. Treatment of seizures with medroxyprogesterone acetate: Preliminary report. Neurology 34 (1984) 1255-1258
39. McAuley J.W., and Anderson G.D. Treatment of epilepsy in women of reproductive age: Pharmacokinetic considerations. Clin. Pharmacokinet. 41 (2002) 559-579
40. Mengel H.B., Houston A., and Back D.J. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J. Pharm. Med. 4 (1994) 141-150
41. Mishell Jr. D.R. Noncontraceptive benefits of oral contraceptives. J. Reprod. Med. 38 (1993) 1021-1029
42. Molich T., Whiteman P., and Orme M. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 32 (1991) 96
43. Morrell M., Sarto G.E., Shafer P.O., Borda E.A., Herzog A., and Callanan M. Health issues for women with epilepsy: A descriptive survey to assess knowledge and awareness among healthcare providers. J. Womens Health Gend. Based Med. 9 (2000) 959-965
44. Mosher W.D., Martinez G.M., Chandra A., Abma J.C., and Willson S.J. Use of contraception and use of family planning services in the United States: 1982-2002. Adv. Data (2004) 1-36
45. O'Brien M.D., and Guillebaud J. Contraception for women with epilepsy. Epilepsia 47 (2006) 1419-1422
46. Odlind V., and Olsson S.E. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception 33 (1986) 257-261
47. Organon USA Inc. NuvaRing Prescribing Information (2005)
48. Perruca E., and Richens A. General principles: Biotransformation. In: Levy R.H., et al. (Ed). Antiepileptic Drugs (1995), Raven Press, New York, NY 31-50
49. Pfizer, Inc. Depo-Provera Contraceptive Injection Product Labeling (2004)
50. Ragueneau-Majlessi I., Levy R.H., and Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43 (2002) 697-702
51. Reimers A., Helde G., and Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentration. Epilepsia 46 9 (2005) 1414-1417
52. Rivera R., Yacobson I., and Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am. J. Obstet. Gynecol. 181 (1999) 1263-1269
53. Rosenberg M.J., Meyers A., and Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 60 (1999) 321-329
54. Rosenfeld W.E., Doose D.R., Walker S.A., and Nayak R.K. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38 (1997) 317-323
55. Russell A., Macpherson H., Cairnie V., and Brodie M.J. The care of pregnant women with epilepsy-A survey of obstetricians in Scotland. Seizure 5 (1996) 271-277
56. Saano V., Glue P., Banfield C.R., Reidenberg P., Colucci R.D., Meehan J.W., Haring P., Radwanski E., Nomeir A., and Lin C.C. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin. Pharmacol. Ther. 58 (1995) 523-531
57. Sabers A., Buchholt J.M., Uldall P., and Hansen E.L. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 47 (2001) 151-154
58. Sabers A., Ohman I., Christensen J., and Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61 (2003) 570-571
59. Saleh W.A., Burkman R.T., Zacur H.A., Kimball A.W., Kwiterovich P., and Bell W.K. A randomized trial of three oral contraceptives: Comparison of bleeding patterns by contraceptive types and steroid levels. Am. J. Obstet. Gynecol. 168 (1993) 1740-1745
60. Seale C., Morrell M.J., Nelson L., and Druzin M.L. Analysis of prenatal and gestational care given to women with epilepsy. Neurology 51 (1998) 1039-1045
61. Shane-McWhorter L., Cerveny J.D., MacFarlane L.L., and Osborn C. Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy. Pharmacotherapy 18 (1998) 1360-1364
62. Shorvon S.D., Tallis R.C., and Wallace H.K. Antiepileptic drugs: Coprescription of proconvulsant drugs and oral contraceptives: A national study of antiepileptic drug prescribing practice. J. Neurol. Neurosurg. Psychiatry 72 (2002) 114-115
63. Sidhu J., Bulsara S., Job S., and Philipson R. A bidirectional pharmacokinetic interaction study of lamotrigine and the combined oral contraceptive pill in healthy subjects. Epilepsia 45 Suppl. 7 (2004) 330
64. Timmer C.J., and Mulders T.M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinet. 39 (2000) 233-242
65. Toivakka E. Oral contraception in epileptics. Arzneimittelforschung 17 (1967) 1085
66. Trussel J. The essentials of contraception: Efficacy, safety, and personal considerations. In: Hatcher R.A., et al. (Ed). Contraceptive Technology (2004), Ardent Media, Inc., New York, NY 221-252
67. Verispan LLC (2005)
68. von Hertzen H., and Van Look P.F.A. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 352 (1998) 428-433
69. Wilbur K., and Ensom M.H. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin. Pharmacokinet. 38 (2000) 355-365
70. World Health Organization (WHO). Medical eligibility criteria for contraceptive use (2004). http://www.who.int/reproductive-health/publications/mec/pocs.html Available at
71. Wright R. Drug interaction with enzyme-inducing drugs. Br. J. Fam. Plann. 15 (1990) 130